



## New Developments in Polio Vaccine

Guest Editor:

**Dr. Konstantin Chumakov**

Division of Viral Products, Center  
for Biologics Evaluation and  
Research, US Food and Drug  
Administration, 10903 New  
Hampshire Avenue, Silver Spring,  
MD 20993, USA

Deadline for manuscript  
submissions:

**20 June 2024**

### Message from the Guest Editor

The discovery of two vaccines against poliomyelitis—first the inactivated poliovirus vaccine (IPV) created by Jonas Salk, and soon after the live oral poliovirus vaccine (OPV) by Albert Sabin—was an enormous medical breakthrough of the mid-20th century. Their creation and use established a paradigm for other vaccines. OPV was so successful that in 1988, the World Health Assembly resolved to completely eradicate poliomyelitis by the year 2000. Even though the deadline was not met and polio eradication remains a moving target 35 years later, the Global Polio Eradication Initiative achieved tremendous progress. It also became clear that the current versions of IPV and OPV are not optimal for a post-eradication world. IPV is made from highly virulent virus strains and does not prevent virus transmission. OPV causes rare but serious adverse events and can trigger new outbreaks caused by a vaccine-derived virus. Therefore, finishing the eradication campaign and making its success irreversible requires the development and introduction of a new generation of polio vaccines. This Special Issue is devoted to these ongoing efforts.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)